SEARCH

SEARCH BY CITATION

References

  • Anonymous (2007) Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791. Drugs in R&D, 8, 113119.
  • Bradstock, K.F., Makrynikola, V., Bianchi, A., Shen, W., Hewson, J. & Gottlieb, D.J. (2000) Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia, 14, 882888.
  • Burger, J.A. & Kipps, T.J. (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107, 17611767.
  • Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J., Tepper, O.M., Bastidas, N., Kleinman, M.E., Capla, J.M., Galiano, R.D., Levine, J.P. & Gurtner, G.C. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine, 10, 858864.
  • Colmone, A., Amorim, M., Pontier, A.L., Wang, S., Jablonski, E. & Sipkins, D.A. (2008) Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science, 322, 18611865.
  • Crazzolara, R., Kreczy, A., Mann, G., Heitger, A., Eibl, G., Fink, F.M., Mohle, R. & Meister, B. (2001) High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 115, 545553.
  • De Clercq, E. (2000) Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Molecular Pharmacology, 57, 833839.
  • Den Boer, M.L., Harms, D.O., Pieters, R., Kazemier, K.M., Gobel, U., Korholz, D., Graubner, U., Haas, R.J., Jorch, N., Spaar, H.J., Kaspers, G.J., Kamps, W.A., Van der Does-Van den Berg, A., Van Wering, E.R., Veerman, A.J. & Janka-Schaub, G.E. (2003) Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 21, 32623268.
  • DiPersio, J.F., Micallef, I.N., Stiff, P.J., Bolwell, B.J., Maziarz, R.T., Jacobsen, E., Nademanee, A., McCarty, J., Bridger, G. & Calandra, G. (2009a) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 47674773.
  • DiPersio, J.F., Stadtmauer, E.A., Nademanee, A., Micallef, I.N., Stiff, P.J., Kaufman, J.L., Maziarz, R.T., Hosing, C., Fruehauf, S., Horwitz, M., Cooper, D., Bridger, G. & Calandra, G. (2009b) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 113, 57205726.
  • Dommange, F., Cartron, G., Espanel, C., Gallay, N., Domenech, J., Benboubker, L., Ohresser, M., Colombat, P., Binet, C., Watier, H. & Herault, O. (2006) CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB Journal, 20, 19131915.
  • Fine, J.P. & Gray, R.J. (1999) A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association, 94, 496509.
  • Hitchon, C., Wong, K., Ma, G., Reed, J., Lyttle, D. & El-Gabalawy, H. (2002) Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis and Rheumatism, 46, 25872597.
  • Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., Nakamura, R., Tanaka, T., Tomiyama, H., Saito, N., Fukata, M., Miyamoto, T., Lyons, B., Ohshima, K., Uchida, N., Taniguchi, S., Ohara, O., Akashi, K., Harada, M. & Shultz, L.D. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature Biotechnology, 25, 13151321.
  • Juarez, J., Bradstock, K.F., Gottlieb, D.J. & Bendall, L.J. (2003) Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia, 17, 12941300.
  • Juarez, J., Dela Pena, A., Baraz, R., Hewson, J., Khoo, M., Cisterne, A., Fricker, S., Fujii, N., Bradstock, K.F. & Bendall, L.J. (2007) CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia, 21, 12491257.
  • Khandany, B.K., Hassanshahi, G., Khorramdelazad, H., Balali, Z., Shamsizadeh, A., Arababadi, M.K., Ostadebrahimi, H., Fatehi, A., Rezazadeh, M., Ahmadi, Z. & Karimabad, M.N. (2012) Evaluation of circulating concentrations of CXCL1 (Gro-alpha), CXCL10 (IP-10) and CXCL12 (SDF-1) in ALL patients prior and post bone marrow transplantation. Pathology, Research and Practice, 208, 615619.
  • Kim, H.K., De La Luz Sierra, M., Williams, C.K., Gulino, A.V. & Tosato, G. (2006) G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood, 108, 812820.
  • Lane, S.W., Scadden, D.T. & Gilliland, D.G. (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood, 114, 11501157.
  • Lilly, A.J., Johnson, W.E. & Bunce, C.M. (2011) The haematopoietic stem cell niche: new insights into the mechanisms regulating haematopoietic stem cell behaviour. Stem Cells International, 2011, 274564.
  • Lowenberg, B., van Putten, W., Theobald, M., Gmur, J., Verdonck, L., Sonneveld, P., Fey, M., Schouten, H., de Greef, G., Ferrant, A., Kovacsovics, T., Gratwohl, A., Daenen, S., Huijgens, P. & Boogaerts, M. (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. New England Journal of Medicine, 349, 743752.
  • Meads, M.B., Hazlehurst, L.A. & Dalton, W.S. (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research, 14, 25192526.
  • Meads, M.B., Gatenby, R.A. & Dalton, W.S. (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nature Reviews. Cancer, 9, 665674.
  • Nervi, B., Ramirez, P., Rettig, M.P., Uy, G.L., Holt, M.S., Ritchey, J.K., Prior, J.L., Piwnica-Worms, D., Bridger, G., Ley, T.J. & DiPersio, J.F. (2009) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood, 113, 62066214.
  • Park, D., Sykes, D.B. & Scadden, D.T. (2012) The hematopoietic stem cell niche. Frontiers in Bioscience (Landmark Edition), 17, 3039.
  • Paweletz, C.P., Charboneau, L., Bichsel, V.E., Simone, N.L., Chen, T., Gillespie, J.W., Emmert-Buck, M.R., Roth, M.J., Petricoin, I.E. & Liotta, L.A. (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene, 20, 19811989.
  • Petricoin, E.F. 3rd, Espina, V., Araujo, R.P., Midura, B., Yeung, C., Wan, X., Eichler, G.S., Johann, D.J. Jr, Qualman, S., Tsokos, M., Krishnan, K., Helman, L.J. & Liotta, L.A. (2007) Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Research, 67, 34313440.
  • Qian, S.X., Li, J.Y., Tian, T., Shen, Y.F., Jiang, Y.Q., Lu, H., Wu, H.X., Zhang, S.J. & Xu, W. (2007) Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leukemia Research, 31, 13831388.
  • R Development Core Team (2013). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Availabel at: http://www.R-project.org/.
  • Rehe, K., Wilson, K., Bomken, S., Williamson, D., Irving, J., den Boer, M.L., Stanulla, M., Schrappe, M., Hall, A.G., Heidenreich, O. & Vormoor, J. (2013) Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Molecular Medicine, 5, 3851.
  • Rombouts, E.J., Pavic, B., Lowenberg, B. & Ploemacher, R.E. (2004) Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood, 104, 550557.
  • Saito, K., Nakamura, Y., Aoyagi, M., Waga, K., Yamamoto, K., Aoyagi, A., Inoue, F., Arai, Y., Tadokoro, J., Handa, T., Tsurumi, S., Arai, H., Kawagoe, Y., Gunnji, H., Kitsukawa, Y., Takahashi, W. & Furusawa, S. (2000) Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. International Journal of Hematology, 71, 238244.
  • Schneider, P., Vasse, M., Al Bayati, A., Lenormand, B. & Vannier, J.P. (2002) Is high expression of the chemokine receptor CXCR-4 of predictive value for early relapse in childhood acute lymphoblastic leukaemia? British Journal of Haematology, 119, 579580.
  • Shen, W., Bendall, L.J., Gottlieb, D.J. & Bradstock, K.F. (2001) The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Experimental Hematology, 29, 14391447.
  • Sipkins, D.A., Wei, X., Wu, J.W., Runnels, J.M., Cote, D., Means, T.K., Luster, A.D., Scadden, D.T. & Lin, C.P. (2005) In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature, 435, 969973.
  • Spoo, A.C., Lubbert, M., Wierda, W.G. & Burger, J.A. (2007) CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood, 109, 786791.
  • Tavernier-Tardy, E., Cornillon, J., Campos, L., Flandrin, P., Duval, A., Nadal, N. & Guyotat, D. (2009) Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leukemia Research, 33, 764768.
  • Teicher, B.A. & Fricker, S.P. (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clinical Cancer Research, 16, 29272931.
  • Vormoor, H.J. (2009) Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited. Cell Cycle, 8, 996999.
  • Wei, G., Ni, W., Chiao, J.W., Cai, Z., Huang, H. & Liu, D. (2011) A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. Journal of Hematology & Oncology, 4, 46.
  • Welschinger, R., Liedtke, F., Basnett, J., Dela Pena, A., Juarez, J.G., Bradstock, K.F. & Bendall, L.J. (2013) Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Experimental Hematology, 41, 293302, e291.
  • Zeng, Z., Shi, Y.X., Samudio, I.J., Wang, R.Y., Ling, X., Frolova, O., Levis, M., Rubin, J.B., Negrin, R.R., Estey, E.H., Konoplev, S., Andreeff, M. & Konopleva, M. (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 113, 62156224.
  • Zuurbier, L., Homminga, I., Calvert, V., te Winkel, M.L., Buijs-Gladdines, J.G., Kooi, C., Smits, W.K., Sonneveld, E., Veerman, A.J., Kamps, W.A., Horstmann, M., Petricoin, E.F. 3rd, Pieters, R. & Meijerink, J.P. (2010) NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia, 24, 20142022.